Sebela Pharmaceuticals Presents Phase 3 Tegoprazan Data in Erosive Esophagitis at Digestive Disease Week® (DDW) 2026

Two oral presentations at DDW 2026 built upon previously reported topline results from the TRIUMpH-EE Phase 3 trials for tegoprazan and covered both erosive esophagitis (EE) healing and maintenance. These presentations highlight tegoprazan's superiority to a PPI, lansoprazole, in healing...